Mablink’s Chief Scientific Officer Warren Viricel presents preclinical data of our drug-linker ADC platform based on the topoisomerase I inhibitor Exatecan vs. HER-2 ADC gold standard Enhertu® in a mouse …
On October 14, during the MATWIN board meeting, Mablink’s COO Valérie Attuil was pitching in front of a panel of investors as part of the 2nd Oncology Upward Investment event. …
Mablink will present preclinical data of our drug-linker ADC platform based on a topoisomerase I inhibitor vs. gold standard Enhertu in a mouse model of gastric cancer.
We are pleased to announce a strategic addition to Mablink’s team with the arrival of Edouard Leroy as our Chief Business Development Officer.
Mablink will take the opportunity to meet with pharmaceutical companies and investors during MEET2WIN, the European oncology partnering convention entirely dedicated to open innovation, collaborative research and technology transfer. Two vibrant days dedicated to oncology and innovation.
Mablink Bioscience is looking forward to the 10th edition of the World ADC congress in London, Europe’s longest standing and most comprehensive forum in the ADC field.
Mablink is adopting Agatha’s solution, a global leader in quality and content management solutions for life sciences.
Mablink receives the support of the Canceropole CLARA to push forward the development of its ADC platform
Mablink receives the iLab 2019 award in the presence of French Minister of Higher Education, Research and Innovation, Mrs Frédérique Vidal, and Bpifrance, at the innovation awards ceremony in Paris.
Mablink receives a €380,000 equity investment from TTO PULSALYS to carry out the preclinical proof of concept of its ADC drug candidate MBK-102 in Non-Hodgkin’s Lymphoma.